Home About Us Solutions Technology Events Contact Us
PCR/ESI-MS References Reports Database

Learn how the IRIDICA technology works

Watch Now

CE Marked. For In Vitro Diagnostic Use. Not commercially available in the United States.

 

Innovative and Smart Technology

IRIDICA combines two Nobel Prize winning technologies to:

 
Bacteria icon
Detect 780 bacteria, Candida and 4 antibiotic resistance markers
Fungus and Virus icon
Detect 200+ fungi and 13 viral reporting groups
Clock icon
Provide the first result in approximately 6 hours

 CE Marked. For In Vitro Diagnostic Use. Not commercially available in the United States.



PCR/ESI-MS Process

Using an innovative new technology combining polymerase chain reaction (PCR) with electrospray ionization mass spectrometry (ESI-MS), IRIDICA provides actionable results.  

PCR/ESI-MS Technology Process 


 

Analytical Performance Studies

RADICAL Study

A multicenter observational study

The RADICAL Study, Rapid Diagnosis of Infection in the Critically Ill, a Multicenter Study of Molecular Detection in Bloodstream Infections, Pneumonia, and Sterile Site Infections,compared results from direct specimen testing using PCR/ESI-MS to results from conventional microbial identification in critically ill patients with suspected severe infections. 

KEY RESULTS:

  • Accurate identification of clinically relevant pathogens 
  • Three-fold enhanced positivity detection rate compared to blood culture
  • 97% NPV compared to culture in suspected bloodstream infections

1. Vincent JL, Brealey D, Libert N, et al. Rapid Diagnosis of Infection in the Critically Ill, a Multicenter Study of Molecular Detection in Bloodstream Infections, Pneumonia, and Sterile Site Infections. Critical Care Medicine.  2015; 43: 2283-2291.



Bacconi Publication

Research solidifying the role of the PCR/ESI-MS technology in the rapid diagnosis of infections in the critically ill

The Bacconi article, Improved Sensitivity for Molecular Detection of Bacteria and Candida Infections in Blood,2 describes a newly developed molecular extraction process that considerably improves the sensitivity of the PCR/ESI-MS analysis of infections in whole blood specimens.

Key Results:

Improvement of sensitivity analysis due to:

  • Ability to process large volume of 5ml of EDTA whole blood 
  • Efficient lysis method and automated DNA purification system
  • Optimization of PCR amplification formulation to tolerate high levels of human DNA

Technology performance in comparison to culture:

  • Two-fold enhanced positivity detection rate
  • 83% sensitive; 94% specific

2. Bacconi A, Richmond GS, Baroldi MA, et al. Improved Sensitivity for Molecular Detection of Bacteria and Candida Infections in Blood. J Clin Microbiol. 2014; 52: 3164-3174. 

Confidence in Results

IRIDICA's easy-to-read Summary Report with interpretable and actionable results. 

Reliable Controls

IRIDICA utilizes pre-filled, DNA-free, sealed and ready-to-use consumables and assays to minimize cross contamination. Four controls further ensure the reliability of each assay.
 
  • Extraction Control
  • Amplification Control
  • Negative Control
  • Control Peptides

CE Marked. For In Vitro Diagnostic Use. Not commercially available in the United States.

Abstract motion
How is the IRIDICA database validated?

The IRIDICA system database is developed and maintained by Abbott Molecular.

  • For organisms with completely sequenced and published genomes, IRIDICA calculates the expected base composition for the region of the microbial genome that is amplified by each assay primer pair.
  • For organisms not yet completely sequenced, IRIDICA obtains a reference standard of the organism and experimentally determines the base composition for each primer pair used in the assay.
  • All base compositions within the database are validated for accuracy.

CE Marked. For In Vitro Diagnostic Use. Not commercially available in the United States.